Study groups+

Lists are limited to individuals profiled in this section. These lists are called study groups+ because they include co-authors of papers published on behalf of study groups. See also a summary of clinical trials.

Merck

CUSP Investigators (Community Based Study of Proscar)
Efficacy, tolerability and effect on health-related quality of life in men with BPH


Finasteride Male Pattern Hair Loss Study Group
Treatment for male pattern hair loss


Finasteride Study Group
Treatment for benign prostatic hyperplasia

The Finasteride 6-year Study Group supported a five-year extension beyond the first year of the Phase III trial. The group consisted of the Finasteride North American Study Investigators, including all individuals listed above, and the Finasteride International Study Investigators, as specified in Lowe 2003.


MTOPS: Medical Therapy of Prostatic Symptoms Research Group
Long-term effect of doxazosin, finasteride & combination therapy on progression of benign prostatic hyperplasia
Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (US)

  • John McConnell, MD, PhD – Steering committee chairman and investigator, University of Texas Southwestern Medical Center, Dallas
  • Stephen Kaplan, MD – Principal Investigator, New York Presbyterian Hospital, New York
  • Claus Roehrborn, MD – Principal Investigator, University of Texas Southwestern Medical Center, Dallas
  • Norman Lepor, MD – Investigator, New York University School of Medicine, New York
  • Kevin McVary, MD – Principal Investigator, Northwestern University, Chicago
  • Gerald Andriole, MD – Principal Investigator, Washington University, St. Louis
  • Merck – ex officio members of the steering committee
    • Elizabeth Round, MD
    • Glenn Gormley, MD
  • Papers: McConnell 1998, Kaplan 2016

PLESS: Finasteride Long-Term Efficacy and Safety Study Group


Primary Care Investigator Study Group
Eficacy and tolerability of finasteride in a primary care setting


PROSPECT: PROscar Safety Plus Efficacy Canadian Two-year Study Group


PROWESS Study Group
Long-term effects of finasteride in patients with benign prostatic hyperplasia 

This international study group did not include any individuals highlighted in this section. The resulting paper was Marberger 1998.


Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
Safety and efficacy of terazosin, finasteride, and the combination of both drugs


GlaxoSmithKline

ARIA Study Investigators
ARIA3001 (US), ARIA3002 (US) & ARIA3003 (19 countries)
Dutasteride as a treatment for benign prostatic hyperplasia

There was also a Chinese trial, ARIA108898, which did not include any of the individuals highlighted in this section.


CombAT: Combination of Avodart and Tamsulosin Study Group
Combination therapy with dutasteride and tamsulosin for benign prostatic hyperplasia


Dutasteride Alopecia Research Team
ARIA2004: Dutasteride vs. finasteride for male pattern hair loss

  • Elise Olsen, MD
  • Vera Price, MD
  • Roger Rittmaster, MD (GSK)
  • Janet Roberts, MD
  • Dow Stough, MD
  • David Whiting, MD
  • Paper: Olsen 2006

EPICS: Enlarged Prostate International Comparator Study
Finasteride vs. dutasteride for benign prostatic hyperplasia

  • J. Curtis Nickel, MD
  • Roger Rittmaster, MD (GSK)
  • Paper: Nickel 2011

REDEEM: Reduction by Dutasteride of Clinical Progression Events in Expectant Management Study Group
Assess whether dutasteride decreases the rate of prostate cancer progression in men with low-risk disease


REDUCE: Reduction by Dutasteride of Prostate Cancer Events Study Group
Determine whether dutasteride reduces the risk of prostate cancer among men at increased risk

  • Gerald Andriole, MD
  • Roger Rittmaster, MD (GSK)
  • Paper: Andriole 2010